Literature DB >> 27653175

Balancing the risks and benefits of prophylaxis: a reply to "Pneumocystis jiroveci pneumonia in patients treated with systemic immunosuppressive agents for dermatologic conditions".

Kyle T Amber1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27653175     DOI： 10.1111/ijd.13395

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN： 0011-9059            Impact factor:   2.736


× No keyword cloud information.
  2 in total

1.  Pneumocystis jirovecii pneumonia in breast cancer mimicking SARS-CoV-2 pneumonia during pandemic.

Authors:  Filippo Castelnuovo; Giorgio Tiecco; Samuele Storti; Benedetta Fumarola; Nigritella Brianese; Davide Bertelli; Francesco Castelli
Journal:  Infez Med       Date:  2021-12-10

2.  Determining the Incidence of Pneumocystis Pneumonia in Patients With Autoimmune Blistering Diseases Not Receiving Routine Prophylaxis.

Authors:  Kyle T Amber; Aniek Lamberts; Farzan Solimani; Arianna F Agnoletti; Dario Didona; Ilona Euverman; Emanuele Cozzani; Lee Haur Yueh; Giovanni Di Zenzo; Yael Anne Leshem; Daniel Mimouni; Michael Hertl; Barbara Horvath
Journal:  JAMA Dermatol       Date:  2017-11-01       Impact factor: 10.282
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.